JP2018516920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516920A5 JP2018516920A5 JP2017561971A JP2017561971A JP2018516920A5 JP 2018516920 A5 JP2018516920 A5 JP 2018516920A5 JP 2017561971 A JP2017561971 A JP 2017561971A JP 2017561971 A JP2017561971 A JP 2017561971A JP 2018516920 A5 JP2018516920 A5 JP 2018516920A5
- Authority
- JP
- Japan
- Prior art keywords
- trastuzumab
- administered
- pharmaceutical
- medicament
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 13
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 229940123237 Taxane Drugs 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021001246A JP7330217B2 (ja) | 2015-05-30 | 2021-01-07 | Ｈｅｒ２陽性転移性乳癌の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168809P | 2015-05-30 | 2015-05-30 | |
| US62/168,809 | 2015-05-30 | ||
| PCT/US2016/034835 WO2016196373A2 (en) | 2015-05-30 | 2016-05-27 | Methods of treating her2-positive metastatic breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001246A Division JP7330217B2 (ja) | 2015-05-30 | 2021-01-07 | Ｈｅｒ２陽性転移性乳癌の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516920A JP2018516920A (ja) | 2018-06-28 |
| JP2018516920A5 true JP2018516920A5 (cg-RX-API-DMAC7.html) | 2019-07-04 |
| JP6822980B2 JP6822980B2 (ja) | 2021-01-27 |
Family
ID=56134616
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561971A Active JP6822980B2 (ja) | 2015-05-30 | 2016-05-27 | Ｈｅｒ２陽性転移性乳癌の治療方法 |
| JP2021001246A Active JP7330217B2 (ja) | 2015-05-30 | 2021-01-07 | Ｈｅｒ２陽性転移性乳癌の治療方法 |
| JP2023064033A Withdrawn JP2023100635A (ja) | 2015-05-30 | 2023-04-11 | Ｈｅｒ２陽性転移性乳癌の治療方法 |
| JP2025105921A Pending JP2025157247A (ja) | 2015-05-30 | 2025-06-23 | Ｈｅｒ２陽性転移性乳癌の治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001246A Active JP7330217B2 (ja) | 2015-05-30 | 2021-01-07 | Ｈｅｒ２陽性転移性乳癌の治療方法 |
| JP2023064033A Withdrawn JP2023100635A (ja) | 2015-05-30 | 2023-04-11 | Ｈｅｒ２陽性転移性乳癌の治療方法 |
| JP2025105921A Pending JP2025157247A (ja) | 2015-05-30 | 2025-06-23 | Ｈｅｒ２陽性転移性乳癌の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11406715B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3302551B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6822980B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107614015A (cg-RX-API-DMAC7.html) |
| DK (1) | DK3302551T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2984592T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3302551T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20241134T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE068105T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3302551T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3302551T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3302551T (cg-RX-API-DMAC7.html) |
| RS (1) | RS65871B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3302551T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016196373A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210330801A1 (en) * | 2017-03-02 | 2021-10-28 | Cadila Healthcare Limited | Novel protein drug conjugate formulation |
| US20200114018A1 (en) * | 2018-10-15 | 2020-04-16 | Genentech, Inc. | Methods of treating residual breast cancer with trastuzumab emtansine |
| JP2022512038A (ja) * | 2018-10-21 | 2022-02-01 | エスエルエスジー リミテッド エルエルシー | トリプルネガティブ乳癌治療のための併用免疫療法 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| ATE155813T1 (de) | 1989-05-19 | 1997-08-15 | Genentech Inc | Her2 extrazellulare domäne |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| EP0950067B1 (en) | 1996-11-27 | 2007-08-29 | Genentech, Inc. | Affinity purification of polypeptide on protein a matrix |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| WO1999048527A1 (en) | 1998-03-27 | 1999-09-30 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
| CN103641885A (zh) | 1998-05-06 | 2014-03-19 | 基因技术股份有限公司 | 用离子交换层析纯化蛋白质 |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| DE60040981D1 (de) | 1999-05-14 | 2009-01-15 | Genentech Inc | BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| PT1189634E (pt) | 1999-06-25 | 2007-06-06 | Genentech Inc | Tratamento de cancro da próstata com anticorpos anti-erbb2. |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| BR0013814A (pt) | 1999-08-27 | 2002-04-23 | Genentech Inc | Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2 |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| CN109395082A (zh) | 2000-05-19 | 2019-03-01 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| SI1501856T1 (sl) | 2002-04-10 | 2013-04-30 | Genentech, Inc. | Variante protitelesa proti HER2 |
| CN101711866A (zh) | 2002-07-15 | 2010-05-26 | 健泰科生物技术公司 | 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法 |
| JP5303092B2 (ja) | 2002-09-11 | 2013-10-02 | ジェネンテック， インコーポレイテッド | タンパク質精製 |
| EP1572972A4 (en) | 2002-11-21 | 2007-11-21 | Genentech Inc | THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES |
| CA2531595C (en) | 2003-07-28 | 2015-12-08 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| US7004206B2 (en) | 2004-01-29 | 2006-02-28 | Viken James P | Automatic fluid exchanger |
| US20060034840A1 (en) | 2004-04-08 | 2006-02-16 | Agus David B | ErbB antagonists for pain therapy |
| RU2404810C9 (ru) | 2004-06-01 | 2015-06-20 | Дженентек, Инк. | Конъюгаты антитело-лекарственное средство и способы |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| KR20150140417A (ko) | 2004-07-22 | 2015-12-15 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ZA200704796B (en) | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
| KR20130089280A (ko) | 2005-01-21 | 2013-08-09 | 제넨테크, 인크. | Ｈｅｒ 항체의 고정 용량 투여법 |
| ES2440481T3 (es) | 2005-02-23 | 2014-01-29 | Genentech, Inc. | Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab |
| US20060204505A1 (en) | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| CA2622755C (en) | 2005-10-07 | 2017-01-31 | Exelixis, Inc. | Azetidines as mek inhibitors |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| KR20090019890A (ko) | 2006-06-05 | 2009-02-25 | 제넨테크, 인크. | Ｅｇｆ 또는 ｔｇｆ-알파 수준이 상승된 암 환자의 생존 연장 |
| AU2007287794B2 (en) | 2006-08-21 | 2013-03-28 | F. Hoffmann-La Roche Ag | Tumor therapy with an anti-VEGF antibody |
| WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
| BRPI0812777A2 (pt) | 2007-06-06 | 2014-12-02 | Hoffmann La Roche | Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir |
| PL2171090T3 (pl) | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| JP5658565B2 (ja) | 2007-09-12 | 2015-01-28 | ジェネンテック， インコーポレイテッド | ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法 |
| EP2215117B2 (en) | 2007-10-30 | 2018-01-10 | Genentech, Inc. | Antibody purification by cation exchange chromatography |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| AR070862A1 (es) | 2008-03-06 | 2010-05-12 | Genentech Inc | Terapia de combinacion con antagonistas de c- met y her |
| DK2644194T3 (en) | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US20110165155A1 (en) | 2009-12-04 | 2011-07-07 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| US20140044709A1 (en) | 2010-12-09 | 2014-02-13 | Genentech, Inc. | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
-
2016
- 2016-05-27 FI FIEP16730123.3T patent/FI3302551T3/fi active
- 2016-05-27 SI SI201631844T patent/SI3302551T1/sl unknown
- 2016-05-27 EP EP16730123.3A patent/EP3302551B1/en active Active
- 2016-05-27 LT LTEPPCT/US2016/034835T patent/LT3302551T/lt unknown
- 2016-05-27 DK DK16730123.3T patent/DK3302551T3/da active
- 2016-05-27 HR HRP20241134TT patent/HRP20241134T1/hr unknown
- 2016-05-27 PL PL16730123.3T patent/PL3302551T3/pl unknown
- 2016-05-27 WO PCT/US2016/034835 patent/WO2016196373A2/en not_active Ceased
- 2016-05-27 JP JP2017561971A patent/JP6822980B2/ja active Active
- 2016-05-27 HU HUE16730123A patent/HUE068105T2/hu unknown
- 2016-05-27 US US15/576,593 patent/US11406715B2/en active Active
- 2016-05-27 RS RS20240909A patent/RS65871B1/sr unknown
- 2016-05-27 PT PT167301233T patent/PT3302551T/pt unknown
- 2016-05-27 ES ES16730123T patent/ES2984592T3/es active Active
- 2016-05-27 CN CN201680031816.8A patent/CN107614015A/zh active Pending
-
2021
- 2021-01-07 JP JP2021001246A patent/JP7330217B2/ja active Active
-
2022
- 2022-07-19 US US17/813,466 patent/US20220354961A1/en not_active Abandoned
-
2023
- 2023-04-11 JP JP2023064033A patent/JP2023100635A/ja not_active Withdrawn
-
2025
- 2025-06-23 JP JP2025105921A patent/JP2025157247A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| JP2017226708A5 (cg-RX-API-DMAC7.html) | ||
| JP2020509024A5 (cg-RX-API-DMAC7.html) | ||
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| RU2020120593A (ru) | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом | |
| JP2012506448A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512513A5 (cg-RX-API-DMAC7.html) | ||
| JP2020523356A5 (cg-RX-API-DMAC7.html) | ||
| JP2016515586A5 (cg-RX-API-DMAC7.html) | ||
| JP2018522028A5 (cg-RX-API-DMAC7.html) | ||
| JP2018526460A5 (cg-RX-API-DMAC7.html) | ||
| NZ723139A (en) | Fgf-18 compound dosing regimen | |
| JP2017514854A5 (cg-RX-API-DMAC7.html) | ||
| JP2018516920A5 (cg-RX-API-DMAC7.html) | ||
| RU2016147521A (ru) | Способы применения антител к ang2 | |
| JP2019534251A5 (cg-RX-API-DMAC7.html) | ||
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| WO2017013490A3 (en) | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer | |
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| FI3302551T3 (fi) | Menetelmiä her2-positiivisen, aiemmin hoitamattoman metastaattisen rintasyövän hoitamiseksi | |
| RU2015145948A (ru) | Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана | |
| JP2020524164A5 (cg-RX-API-DMAC7.html) | ||
| JP2016522826A5 (cg-RX-API-DMAC7.html) |